Keyphrases
Acute Myeloid Leukemia
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
82%
Reduced-intensity Conditioning
45%
Overall Survival
33%
Graft-versus-host Disease (GvHD)
24%
Leukemia Patients
22%
Hazard Ratio
18%
Non-relapse Mortality
18%
Confidence Interval
18%
De Novo Acute Myeloid Leukemia
17%
FMS-like Tyrosine Kinase 3 (FLT3)
17%
Fludarabine
15%
FLT3 mutation
15%
Chemotherapy
15%
Transplantation
15%
Complete Remission
13%
High Risk
13%
Chronic Lymphocytic Leukemia
12%
Bone Marrow
12%
Multivariate Analysis
12%
HLA-identical Sibling
12%
Hematological Malignancies
12%
Midostaurin
11%
Risk Factors
10%
Prognostic Impact
10%
Pretransplant
10%
Hematopoietic Transplantation
10%
Unrelated Donor
10%
Leukemia-free Survival
9%
Marrow Transplantation
9%
Minimal Residual Disease
9%
Infection-related Mortality
9%
Adult Patients
9%
Myelodysplastic Syndrome
9%
Cytarabine
9%
Intermediate Cytogenetic Risk
9%
American Society
9%
Allo-RIC
8%
Annualized Relapse Rate
8%
Cumulative Incidence
8%
Follicular Lymphoma
8%
FLT3-ITD
8%
Severe Infection
8%
Acute Leukemia
8%
Quantitative PCR
8%
Lymphoma
8%
Idarubicin
7%
Spain
7%
GVHD Prophylaxis
7%
B-cell Lymphoma
7%
Medicine and Dentistry
Acute Myeloid Leukemia
78%
Reduced Intensity Conditioning
40%
Overall Survival
34%
Allogeneic Stem Cell Transplantation
29%
Hematopoietic Cell
28%
Cell Transplantation
27%
Chemotherapy
23%
Diseases
23%
Allogeneic Hematopoietic Stem Cell Transplantation
20%
Transplantation
17%
Graft Versus Host Reaction
17%
Hazard Ratio
16%
Cumulative Incidence
15%
De Novo Acute Myeloid Leukemia
13%
B-Cell Chronic Lymphocytic Leukemia
12%
Hematopoietic Stem Cell Transplantation
12%
Infection
12%
Myelodysplastic Syndrome
11%
Conditioning
11%
Acute Graft Versus Host Disease
10%
Minimal Residual Disease
9%
Midostaurin
9%
High Risk Population
9%
Leukemia
9%
Multivariate Analysis
9%
Follicular Lymphoma
9%
Non-Relapse Mortality
9%
Prognostic Factor
8%
Iron Overload
7%
Stem Cell Therapy
7%
Flow Cytometry
7%
Comorbidity
7%
Hematologic Malignancy
7%
Fludarabine
7%
Hematology
6%
Neoplasm
6%
Cytarabine
6%
Diffuse Large B-Cell Lymphoma
6%
Lymphoma
5%
Engraftment
5%
Gene Expression
5%
Rituximab
5%
Prospective Study
5%
Multiple Myeloma
5%
microRNA
5%
B-Cell Lymphoma
5%
Rapamycin
5%
Core Binding Factor
5%
Natural Killer Cell
5%
Cord Blood
5%